Skip to content
Biodatica
Start free

KEYSTONE SYMPOSIA

SILVERTHORNE, CO

OncologymRNAGrant-only
Compare Sign in to watch

What changed

NIH R13 · $0.0M · Tumor Microenvironment: Identifying Drivers of Progression and Resistance

2mo agoNew grantMay 4, 2026Source filing (opens the source filing in a new tab)

Momentum

79no change

Momentum 79 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

8,721 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R13 · $5k · non-dilutive

    May 1, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NCI · award ends Apr 30, 2027 · Tumor Microenvironment: Identifying Drivers of Progression and Resistance

    NIH RePORTER · NIH RePORTER 11392747 (opens the source filing in a new tab)

  2. Grant

    R13 · $5k · non-dilutive

    Mar 3, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NCI · award ends Feb 28, 2027 · Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations

    NIH RePORTER · NIH RePORTER 11321075 (opens the source filing in a new tab)

  3. Grant

    R13 · $10k · non-dilutive

    Mar 3, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NCI · award ends Feb 28, 2027 · RNA Modifications: Bridging Biological Function and Therapeutic Potential

    NIH RePORTER · NIH RePORTER 11320647 (opens the source filing in a new tab)

  4. Grant

    R13 · $17k · non-dilutive

    Feb 10, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NIAID · award ends Jan 31, 2027 · Myeloid Cells: Functional Heterogeneity with Therapeutic Promise

    NIH RePORTER · NIH RePORTER 11321056 (opens the source filing in a new tab)

  5. Grant

    R13 · $21k · non-dilutive

    Feb 5, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NINDS · award ends Jan 31, 2027 · Mitochondria Signaling in Physiology and Disease

    NIH RePORTER · NIH RePORTER 11320593 (opens the source filing in a new tab)

  6. Grant

    R13 · $12k · non-dilutive

    Feb 1, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NHLBI · award ends Jan 31, 2027 · Hematopoiesis

    NIH RePORTER · NIH RePORTER 11321049 (opens the source filing in a new tab)

  7. Grant

    R13 · $18k · non-dilutive

    Jan 20, 2026

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NCATS · award ends Dec 31, 2026 · iPSCs: Progress, Opportunities, and Challenges

    NIH RePORTER · NIH RePORTER 11320460 (opens the source filing in a new tab)

  8. Grant

    R13 · $20k · non-dilutive

    Aug 6, 2025

    KEYSTONE SYMPOSIA · PI SHEPPARD, TERRY L. · NCI · award ends Jul 31, 2026 · Spotlight on the Cancer Cell: Intrinsic Properties and Vulnerabilities for Therapeutics

    NIH RePORTER · NIH RePORTER 11247281 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources